Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQianfoshan Hospital
About this trial
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis.
Meets the diagnostic criteria for fungal-sensitized asthma.
Disqualifiers
Human immunodeficiency virus infection.
Malignant tumor.
Blood system disease.
autoimmune system disease.
Trial population
The patients with allergic bronchopulmonary aspergillosis and fungal-sensitized asthma who were treated in several hospitals were included as the study objects, and the relatively normal ones who had no bronchial asthma and no fungal sensitization were matched by gender and age as the control group, and then the cohorts of patients with allergic bronchopulmonary aspergillosis, fungal-sensitized asthma and the control group were established.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
- Other intervention
No intervention
Treatment groups
140 Participants
are divided into 3 treatment groupsGroup A: allergic bronchopulmonary aspergillosis0 interventions
Group B: fungal-sensitized asthma0 interventions
Group C: control group0 interventions
Trial outcomes
Primary outcomes
1
Total serum IgE
Time frame
Up to 12 monthsSecondary outcomes
1
Aspergillus-specific IgE
Time frame
Up to 12 months2
Aspergillus-specific IgG
Time frame
Up to 12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Qianfoshan Hospital
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Collaborator
Fudan University
Collaborator
Guizhou Provincial People's Hospital
Collaborator
The First Hospital of Jilin University
Collaborator
Qilu Hospital of Shandong University
Collaborator
Source ClinicalTrials.gov